The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Myeloma XI trial: impact of MRD on treatment response in MM
Minimal residual disease (MRD) is the major cause of relapse in multiple myeloma (MM), and measurements of its level can be utilized to determine treatment response and prognosis. Here, Graham Jackson, FRCP, FRCPath, MD, of Newcastle University, Newcastle, UK, discusses the impact of MRD status and cytogenetics on the treatment response of MM patients in the Phase III Myeloma XI trial (NCT01554852), which investigated the benefit of lenalidomide maintence therapy. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
